Financial Data and Key Metrics Changes - Total revenue for Q1 2025 was $17.8 million, up from $15.8 million in Q1 2024, representing a year-over-year growth of 13% [32] - On a constant currency basis, revenue growth was 15%, with foreign exchange headwinds negatively impacting reported revenue by approximately $0.4 million [32] - Adjusted EBITDA loss improved by 24% year-over-year, reaching $9.8 million in Q1 2025 compared to $12.9 million in Q1 2024 [36] - Adjusted gross margin reached a record high of 75.7%, up from 70.6% in the prior year [34] Business Line Data and Key Metrics Changes - Core genomic customers increased to 490 as of March 31, 2025, up from 463 in the prior year [32] - The company implemented 33 new customers in Q1 2025, compared to an average of 23 per quarter in 2024 [8][32] - Hematology-oncology (HemOnc) volumes grew 34% year-over-year in Q1 2025, with over 180 HemOnc customers globally [21] Market Data and Key Metrics Changes - Revenue and analysis volume from U.S. core genomic customers grew over 30% year-over-year [9] - UK analysis volume grew over 60% year-over-year, with UK revenue up approximately 80% [20] - North America and Asia Pacific outperformed with 3240% year-over-year volume growth respectively [19] Company Strategy and Development Direction - The company aims to capitalize on new customer signings by expediting implementation times and expanding across those accounts over time [8] - Focus areas for growth in 2025 include the U.S. market, new applications like MSK Access and MSK Impact, and partnerships with biopharma [9][11] - The company is positioned to leverage its scalable cloud-based platform to support medical innovations and drive future growth [15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth potential, citing the increasing demand for data-driven medicine and the company's unique AI capabilities [44] - The company reaffirmed its full-year revenue guidance for 2025 of $70 million to $76 million, representing 10% to 17% growth [38] - Management noted that while Q1 results were strong, they expect the year to be back-half weighted due to the timing of new business coming online [38][94] Other Important Information - The company finished Q1 2025 with approximately $68.5 million in cash and cash equivalents, plus access to an additional $35 million in capital [37] - The company is focused on maintaining operational efficiencies while continuing to invest in high ROI projects [36] Q&A Session Summary Question: Actions taken to accelerate implementation times - Management highlighted that they have scaled up team capabilities, created tooling and automation, and increased headcount in wet lab and field application scientists to speed up the implementation process [48][50] Question: Average contract value increase and enterprise sales - Management confirmed that 58% of customers are using two or more applications, indicating room for expansion. They noted that enterprise sales involve signing for a majority of applications, which is driving the increase in average contract value [55][56] Question: Sustainability of gross margins above 75% - Management acknowledged that while Q1 gross margins were higher than expected due to a favorable mix, they still anticipate year-over-year improvements in gross margins moving forward [66] Question: Biopharma side opportunities and guidance - Management indicated that while they expect the biopharma segment to be flat in 2025, they are seeing good momentum and opportunities in the pipeline, particularly in companion diagnostics and sponsored testing [70] Question: Balance sheet sufficiency for adjusted EBITDA breakeven target - Management confirmed that with over $100 million in available liquidity, they are well-positioned to reach their adjusted EBITDA breakeven target by 2027 [90]

Weave Overview Q1 2025 NYSE : WEAV MAY 2025 1 Safe Harbor Statement This presentation has been prepared by Weave Communications, Inc. ("Weave", "we", "us", or "our") for informational purposes only and not for any other purpose. This presentation contains "forward-looking statements" within the Private Securities Litigation Reform Act of 1995 that are based on our management's current expectations and projections about future events and financial trends that we believe may affect our financial condition, re ...

Weave Communications (WEAV) Q1 2025 Earnings Call May 05, 2025 04:30 PM ET Company Participants Mark McReynolds - Head of Investor RelationsBrett White - CEOJason Christiansen - CFOTimothy Greaves - Equity Research Associate Conference Call Participants Alex Sklar - AnalystBrent Bracelin - Sr. Research AnalystParker Lane - AnalystMichael Funk - Analyst Operator Ladies and gentlemen, greetings and welcome to the Vii First Quarter '20 '20 '5 Financial Results. At this time, all participants are in a listen on ...

Q1 revenue growth of 14% year-over-yearQ1 net income of $29.3 million and non-GAAP net income of $58.7 million Q1 net income margin of 11%; adjusted EBITDA margin of 42% Raising revenue and adjusted EBITDA guidance for 2025LEHI, Utah and LOUISVILLE, Ky., April 30, 2025 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today reported results for the first quarter ended March 31, 2025."Waystar sustained strong momentum in the first quarter of 2025, deliver ...

Financial Data and Key Metrics Changes - The company reported revenues of $87.1 million for Q1 2025, marking a 62% year-over-year growth in Exome and Genome revenues, which contributed $71.4 million this quarter [16][22] - Adjusted gross profit from continuing operations was $59.7 million, up 56% year-over-year, resulting in an adjusted gross margin of 69%, an increase from 61% a year ago [21][22] - Adjusted net income for Q1 2025 was $7.7 million, representing the third consecutive quarter of profitability [22] Business Line Data and Key Metrics Changes - Exome and Genome tests accounted for 40% of all tests in Q1, with volumes from these flagship products up 24% year-over-year [16] - The company launched its ultra-rapid genome sequencing product, which delivers results in as soon as 48 hours, enhancing its service offerings [10][19] Market Data and Key Metrics Changes - The company grew its market penetration of pediatric neurologists to 14% [9] - Average reimbursement rate for Exome and Genome tests increased to approximately $3,400, up from $2,600 in the same quarter last year [20] Company Strategy and Development Direction - The company is focused on integrating exome and genome testing as a standard of care, aiming to shift from reactive to proactive healthcare [7][8] - Plans to acquire Fabric Genomics, which will enhance AI-powered genomic interpretation and create a recurring software-based revenue stream [12][13] - The company is expanding into new clinical indications and markets, including NICU and adult testing, to capture growth opportunities [10][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the strategic fit of the Fabric acquisition and its potential to unlock scalable platform economics [13] - The company anticipates continued growth in its core exome and genome testing business, with a guidance increase for total revenues to between $360 million and $375 million for the full year 2025 [23][25] Other Important Information - The company highlighted the importance of newborn screening and its potential revenue contribution, expected to materialize around 2027 [46] - Management noted that only 5% of rare diseases currently have approved therapies, emphasizing the critical role of genomic data in drug discovery [14] Q&A Session Summary Question: What are the reasons for the sequential decline in volumes in Q1? - Management acknowledged a historical pattern of volume decline from Q4 to Q1, exacerbated by weather disruptions and fewer sales days in Q1 [30][31] Question: What contributed to the increase in G&A expenses? - A significant portion of the increase was attributed to costs related to the Epic integration and general support costs, with expectations of driving down OpEx as a percentage of revenue over time [34][35] Question: What visibility supports the expected acceleration in NICU volumes in the second half of the year? - Management indicated that initial integration with Epic is on track and that there is a solid pipeline of clients ready to come online [38] Question: How is pricing expected to play out in Q2 and beyond? - Management noted that the average reimbursement rate is expected to remain stable, with ongoing efforts to reduce denials and improve the revenue cycle [40][43] Question: What is the expected impact of the weather disruptions on Q2 volumes? - Management expects to recoup some of the missed appointments in Q2, although long wait times for specialist appointments may affect recovery [90] Question: What are the expectations for new indications this year? - Management confirmed that new indications, including immune deficiencies and cerebral palsy, are expected to contribute to growth, although it is too early to quantify their impact [63][65]

DarioHealth Corp. (NASDAQ:DRIO) Q4 2024 Earnings Conference Call March 10, 2025 8:30 AM ET Company Participants Kat Parrella - Investor Relations Manager Erez Raphael - Chief Executive Officer Steven Nelson - Chief Commercial Officer Conference Call Participants Charles Rhyee - TD Cowen Ashok Kumar - ThinkEquity David Grossman - Stifel Operator Good morning, ladies and gentlemen, and welcome to the DarioHealth Fourth Quarter 2024 Results Conference Call. At this time, all lines are in listen-only mode. Foll ...

eHealth, Inc. (NASDAQ:EHTH) Q4 2024 Earnings Conference Call February 26, 2025 8:30 AM ET Company Participants Fran Soistman - Chief Executive Officer John Dolan - Chief Financial Officer Kate Sidorovich - Senior Vice President, Investor Relations and Strategy Eli Newbrun-Mintz - Senior Investor Relations Manager Conference Call Participants George Sutton - Craig Hallum Ben Hendrix - RBC Capital Markets Jonathan Yong - UBS George Hill - Deutsche Bank Operator Good morning, everyone, and welcome to eHealth I ...

Doximity, Inc. (NYSE:DOCS) Q3 2025 Earnings Conference Call February 6, 2025 5:00 PM ET Company Participants Perry Gold - Vice President of Investor Relations Jeff Tangney - Co-Founder and Chief executive Officer Nate Gross - Co-Founder and Chief Strategy Officer Anna Bryson - Chief Financial Officer Conference Call Participants Brian Peterson - Raymond James Glen Santangelo - Jefferies Ryan Daniels - William Blair Ryan MacDonald - Needham & Company Elizabeth Anderson - Evercore ISI Richard Close - Canaccor ...